New hope for rare blood cancer: testing Triple-Drug attack
NCT ID NCT07165769
Summary
This study is testing a new combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—for people newly diagnosed with a rare blood cancer called SBLPN. The goal is to see if this three-drug approach is safe and effective at controlling the disease. Researchers will enroll about 47 patients who have not had prior treatment to measure how well the cancer responds and how long the benefits last.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
Conditions
Explore the condition pages connected to this study.